Record pricing gains mask commodity dependence; Q2 headwinds loom

Delivered 39.7% YoY, 31.7% QoQ. Essentials +50%, Specialty +17%. Price-driven, not organic volume.

If 40% total and 10% volume, 30% is price/mix. Consistent with the split.

Q1 OPM 11.8%. Management cautions this is upside outlier; cycle average mid-single-digit, vs Q3 FY26 low single-digit.

Acknowledged. Tied to precautionary raw material stocking amid volatility. Cash headwind until normalization.

Timeline confirmed. Customer qualification Q3, ramp Q4. No FY28 revenue quantum disclosed.

Specialty +17% YoY vs Essentials +50%; weaker momentum. 20–25% deferred post-ramp; 'might not be there short term'.

Prior call expected 'good start to FY27'. Q1 delivered 39.7% YoY revenue, 216.6% PAT growth, well above baseline. Upgrade driven by commodity tailwind (acetic acid 200% spike, ethyl acetate spreads above 12-year average), not structural.

No numeric FY27 margin target set or revised. Management reaffirmed mid-single-digit cyclic target; Q1 11–12% flagged as upside outlier, not new normal.

No full-year FY27 revenue or margin target provided. Management withheld ('bear with us'), citing forward uncertainty. Deferred to later call for FY28 guidance.

Management explicitly cautious on Q2 ('too early to say') due to West Asia 2.0 crisis, South China typhoon disruptions. Leading indicators show continued volatility in acetic acid, methanol.

Full-year capex ₹125–150 Cr. Phase 2 85% capex capitalizes in Q2. FY28 revenue/EBITDA guidance deferred. Ramp Q4 FY27, then Q3/FY29 focus. Doubling diketene capability; strategy to penetrate segments.

No straight answer. Essentials cyclic; need over-the-cycle view. Q3 FY26 pressure, now Q1 upside. Important: right to operate (scale, integration, upcycle benefits). Specialty also recovering post-FY26 feedstock deflation.

Enterprise: 10% volume growth, rest from price and product mix. Multiple products; hard to pin down precisely.

Essentials cyclic, steered with agility. End-to-end, customer relationships strong. Too premature for specifics. 11–12% EBITDA gives us right to expand.

COVID paracetamol surge increased anhydride demand; now muted. But seeing positive momentum currently.

World-scale ethyl acetate capacity at Lote now online. Dahej Phase 1 at good utilization, ramping with customer. Phase 2 taking shape. Laxmi has track record of ramping, not running idle. Numbers shared as conversation progresses.

Project Vaayu on track. Mechanical completion early Q3. Ramp-up with partner thereafter. FY28 capacity available; scale-up expected.

Still leader in electrochemical fluorination. Robust specialty pipeline leveraging technology. Partnerships TBA in due course. Stay tuned.

FY26 impacted by phaseout of 10% revenue product and deflationary feedstock pricing (−25%). Site 2 was fully utilized pre-Dahej; bottom-sliced portfolio. Dahej Phase 2 now opens constrained products. Specialty batch/seasonal/campaign; need 2–3 year view. Aspire 20–25% historically; might not be short term due to ramp.

Depreciation increases from Q2 when Phase 2 capitalizes. Tentative ₹7–7.5 Cr incremental/quarter. Debt repayment starts next year, continues 5 years.

Q1 delivered 39.7% YoY, but management withheld FY27 annual target. Flagged Q2 volatility.

Mechanical completion Q2, qualification Q3, ramp Q4. No FY28 revenue quantum disclosed.

Mechanical completion early Q3. Ramp-up FY28+. No specific revenue or timeline for material contribution.

Q1 11–12% flagged as upside outlier. Q3 FY26 low single-digit. Cyclic; mid-single-digit normalized target.

Currently ramping. Management: 'might not be there short term'. Deferred to post-ramp visibility.

Dahej Phase 2 85% capitalization Q2. Incremental depreciation ₹7–7.5 Cr/quarter from Q2 onwards.

Acetic acid, methanol, ethyl acetate spiked 200%+ in March. Q1 benefited from high spreads (ethyl acetate above 12-year average of $215–220). Normalization/deflation will compress margins sharply, especially Essentials.

West Asia 2.0 crisis, Gulf of Hormuz, Red Sea tensions, South China typhoon creating vessel scarcity and transportation bottlenecks. Q2 explicitly flagged by management as volatile.

Net working capital increased Q1 due to precautionary raw material stocking. If inventory doesn't convert or receivables stretch, material cash impact.

Essentials EBITDA swings from low single-digit (Q3 FY26) to 11–12% (Q1 FY27). Cyclic; Q1 is upside outlier. Reversion to mid-single-digit normalized target will disappoint consensus.

Specialty +17% YoY vs Essentials +50%, indicating weaker growth. FY26 impacted by product phaseout (10% revenue) and feedstock deflation. Management aspires 20–25% but cautions 'might not be short term'. Timeline unclear.